RetinoStat® Gene Therapy for the Treatment of Wet AMD: Oxford BioMedica
Description: Oxford BioMedica (U.K.) is conducting a Phase I clinical trial of RetinoStat® for the treatment of wet age-related macular degeneration (AMD). The treatment involves the delivery of a gene that produces a protein which halts the production of vascular endothelial growth factor (VEGF). VEGF is a protein that leads to the proliferation of leaky blood vessels underneath the retina that causes vision loss in wet AMD. A lentivisrus is used for gene delivery. As many as 18 participants will be enrolled in the study. Three doses of the treatment are being evaluated.
Trial Status: Recruiting participants.
Clinical Trial for Wet AMD Gene Therapy to Begin in December 2010
Partial List of Participation Criteria:
- 50 years of age or older
- Diagnosis of wet age-related macular degeneration
Peter Campochiaro, M.D.
Johns Hopkins University Hospital
RetinoStat clinical trial listing on ClinicalTrials.gov